CN1703209A - 通过静脉施用卤化挥发性麻醉药保护心脏和保护神经的方法 - Google Patents

通过静脉施用卤化挥发性麻醉药保护心脏和保护神经的方法 Download PDF

Info

Publication number
CN1703209A
CN1703209A CNA2003801012256A CN200380101225A CN1703209A CN 1703209 A CN1703209 A CN 1703209A CN A2003801012256 A CNA2003801012256 A CN A2003801012256A CN 200380101225 A CN200380101225 A CN 200380101225A CN 1703209 A CN1703209 A CN 1703209A
Authority
CN
China
Prior art keywords
patient
amount
preparation
ischemic event
isoflurane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2003801012256A
Other languages
English (en)
Chinese (zh)
Inventor
劳尔·特里洛
拉尔夫·莱瑟
萨蒂什·佩亚韦尔
纳夫尼特·普里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter International Inc
Original Assignee
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter International Inc filed Critical Baxter International Inc
Publication of CN1703209A publication Critical patent/CN1703209A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2003801012256A 2002-10-11 2003-10-09 通过静脉施用卤化挥发性麻醉药保护心脏和保护神经的方法 Pending CN1703209A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41793402P 2002-10-11 2002-10-11
US60/417,934 2002-10-11

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2011101820964A Division CN102283821A (zh) 2002-10-11 2003-10-09 含有卤化挥发性麻醉药的制剂在制备通过肠外给药用于治疗组织具有缺血事件的患者的制剂中的应用

Publications (1)

Publication Number Publication Date
CN1703209A true CN1703209A (zh) 2005-11-30

Family

ID=32094122

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2003801012256A Pending CN1703209A (zh) 2002-10-11 2003-10-09 通过静脉施用卤化挥发性麻醉药保护心脏和保护神经的方法
CN2011101820964A Pending CN102283821A (zh) 2002-10-11 2003-10-09 含有卤化挥发性麻醉药的制剂在制备通过肠外给药用于治疗组织具有缺血事件的患者的制剂中的应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2011101820964A Pending CN102283821A (zh) 2002-10-11 2003-10-09 含有卤化挥发性麻醉药的制剂在制备通过肠外给药用于治疗组织具有缺血事件的患者的制剂中的应用

Country Status (19)

Country Link
US (1) US7999011B2 (ko)
EP (1) EP1558226B1 (ko)
JP (1) JP5210486B2 (ko)
KR (2) KR101403264B1 (ko)
CN (2) CN1703209A (ko)
AT (1) ATE546136T1 (ko)
AU (1) AU2003282464B2 (ko)
BR (1) BR0314617A (ko)
CA (1) CA2500310C (ko)
DK (1) DK1558226T3 (ko)
ES (1) ES2382911T3 (ko)
HK (1) HK1079703A1 (ko)
IL (1) IL167472A (ko)
MX (1) MXPA05003741A (ko)
NZ (1) NZ539298A (ko)
PL (1) PL219493B1 (ko)
RU (1) RU2350323C2 (ko)
WO (1) WO2004032858A2 (ko)
ZA (1) ZA200502741B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102014961B (zh) * 2008-01-22 2017-10-13 得克萨斯大学体系董事会 用于局部麻醉和/或疼痛缓解的含有萃取溶剂的挥发性麻醉剂组合物

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04002446A (es) 2001-09-26 2004-07-23 Baxter Int Preparacion de nanoparticulas de tamano de submicras mediante dispersion y remocion de la fase liquida o solvente.
US20080119820A1 (en) 2006-09-20 2008-05-22 Phan Phillip C Methods for Delivering Volatile Anesthetics for Regional Anesthesia and/or Pain Relief
GB0619499D0 (en) 2006-10-03 2006-11-08 Lucent Technologies Inc Encrypted data in a wireless telecommunications system
DE112008002914A5 (de) * 2007-11-06 2010-09-30 B. Braun Melsungen Ag Einen hydrophoben Wirkstoff enthaltende wässrige Emulsionen
WO2009094460A2 (en) 2008-01-22 2009-07-30 Vapogenix, Inc. Volatile anesthetic compositions and methods of use
AU2015200210B2 (en) * 2008-01-22 2016-08-11 The Board Of Regents Of The University Of Texas System Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief
JP2012526133A (ja) * 2009-05-05 2012-10-25 ベイポジェニックス インコーポレイテッド 炎症を低減させるための新規揮発性麻酔薬製剤およびその使用法
US20120219596A1 (en) 2009-07-30 2012-08-30 Wendelin Stark Injectable formulation for treatment and protection of patients having an inflammatory reaction or an ischemia-reperfusion event
FR2956323B1 (fr) * 2010-02-15 2013-12-20 Air Liquide Medicament gazeux inhalable a base d'argon contre les deficiences ou defaillances d'organes peripheriques
CN103764128A (zh) 2011-06-24 2014-04-30 维普詹尼克斯公司 用于治疗皮肤病症或疾病的新型制剂和方法
AU2014227996B2 (en) 2013-03-15 2018-08-23 Vapogenix, Inc. Novel analgesic compositions
ITMO20130075A1 (it) * 2013-03-22 2014-09-23 Enrico Giuliani Dispositivo di somministrazione

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1018773A (en) * 1962-09-13 1966-02-02 Bellon Labor Sa Roger ª‡-phenyl-ª‰-2-furyl-propionitrile derivatives
US4073943A (en) 1974-09-11 1978-02-14 Apoteksvarucentralen Vitrum Ab Method of enhancing the administration of pharmalogically active agents
US5628930A (en) 1992-10-27 1997-05-13 Alliance Pharmaceutical Corp. Stabilization of fluorocarbon emulsions
US5635538A (en) 1993-03-16 1997-06-03 Alliance Pharmaceutical Corp. Fluorocarbon emulsions with reduced pulmonary gas-trapping properties
JP2961034B2 (ja) * 1993-09-16 1999-10-12 アルプス電気株式会社 磁気ヘッド
WO1995008544A1 (en) * 1993-09-24 1995-03-30 The University Of British Columbia Aminocyclohexylesters and uses thereof
FR2726267B1 (fr) * 1994-10-26 1998-01-02 Smithkline Beecham Lab Nouveaux agents anti-arythmiques, compositions pharmaceutiques les contenant, et procede pour les preparer
GB2350297A (en) 1999-05-27 2000-11-29 Abbott Lab Injectable halogenated anesthetic formulation in emulsion form
EP1311270B1 (en) * 2000-07-26 2008-01-09 Taro Pharmaceutical Industries Limited Non-sedating barbiturate compounds as neuroprotective agents

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102014961B (zh) * 2008-01-22 2017-10-13 得克萨斯大学体系董事会 用于局部麻醉和/或疼痛缓解的含有萃取溶剂的挥发性麻醉剂组合物

Also Published As

Publication number Publication date
US20040127578A1 (en) 2004-07-01
JP2006504740A (ja) 2006-02-09
IL167472A (en) 2013-10-31
EP1558226B1 (en) 2012-02-22
HK1079703A1 (zh) 2006-04-13
EP1558226A2 (en) 2005-08-03
BR0314617A (pt) 2005-08-02
JP5210486B2 (ja) 2013-06-12
PL376217A1 (en) 2005-12-27
ATE546136T1 (de) 2012-03-15
MXPA05003741A (es) 2005-06-17
KR20050056230A (ko) 2005-06-14
US7999011B2 (en) 2011-08-16
RU2005114008A (ru) 2005-10-27
ES2382911T3 (es) 2012-06-14
AU2003282464B2 (en) 2010-02-25
CA2500310A1 (en) 2004-04-22
RU2350323C2 (ru) 2009-03-27
KR20120030598A (ko) 2012-03-28
PL219493B1 (pl) 2015-05-29
CN102283821A (zh) 2011-12-21
WO2004032858A3 (en) 2004-09-23
ZA200502741B (en) 2006-02-22
CA2500310C (en) 2013-03-12
DK1558226T3 (da) 2012-05-07
EP1558226A4 (en) 2008-04-02
WO2004032858A2 (en) 2004-04-22
NZ539298A (en) 2008-11-28
AU2003282464A1 (en) 2004-05-04
KR101403264B1 (ko) 2014-06-02

Similar Documents

Publication Publication Date Title
US10799466B2 (en) Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief
Marcilla et al. Influence of a constant rate infusion of dexmedetomidine on cardiopulmonary function and recovery quality in isoflurane anaesthetized horses
VESAL et al. Postoperative analgesic and cardiopulmonary effects in dogs of oxymorphone administered epidurally and intramuscularly, and medetomidine administered epidurally: a comparative clinical study
CN1703209A (zh) 通过静脉施用卤化挥发性麻醉药保护心脏和保护神经的方法
Swindle et al. Perioperative Care
JP2011102290A (ja) 人工心肺に関連する神経障害を制御するためのキセノンの使用
WO2020168213A1 (en) Methods for evaluating treatments and physiology in human patients using intravenous alpha-2 adrenergic antagonist agents
CN105726472B (zh) 苯达莫司汀药剂组合物及应用
JP2006504740A5 (ko)
CN100475200C (zh) 异丙酚口服麻醉药及其制备方法
Li et al. Effect of dexmedetomidine on analgesia and sedation of sufentanil during anesthesia induction period of gynecological surgery.
WO2016102463A1 (en) Combination of remifentanil and propofol
Marshall et al. Interaction between negative inotropic effects of halothane and nifedipine in the isolated rat heart
Dong et al. Role of methadone in extracorporeal membrane oxygenation: Two case reports
Bednarski Anesthesia management of dogs and cats
CN109172550A (zh) 一种复合麻醉药物
Moshinsky et al. Malignant Hyperthermia During Sleeve Lobectomy for Resection of a Proximal Endobronchial Tumor
RU2205632C1 (ru) Способ анестезиологического пособия у детей с ожогами
Jamuna A prospective randomised study on comparison of induction dose requirements and hemodynamic alterations of midazolam-propofol and propofol-propofol coinduction in patients undergoing elective general surgery.
Guo et al. Determination of Alfaxalone Dose for Co-Induction with Dexmedetomidine and the Clinical Efficacy in Cats

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1079703

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20051130

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1079703

Country of ref document: HK